Pancreatic Cancer Research

ResearcherYonsei UniversityActive in the last 2 years

Sung Hyun Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7683-9687; OpenAlex author ID A5100450425, A5128061670. Sources: OpenAlex.

Their work

Papers
23 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
1
Collaborators
30
Papers, trials and grants by year

2016: 1 paper · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 3 papers · 2022: 4 papers · 2023: none · 2024: 2 papers · 2025: 5 papers · 2026: 4 papers

Papers 23

  1. Comparison of Long-Term Oncologic and Perioperative Outcomes of Minimally Invasive and Open Pancreatoduodenectomy for Resectable and Borderline Resectable Panc… Co-author DOI 10.1002/jhbp.70063↗
  2. Feasibility and safety of minimally invasive distal pancreatosplenectomy in resectable and borderline resectable pancreatic cancer following neoadjuvant chemot… Co-author DOI 10.1007/s00464-025-12533-3↗
  3. Long-term oncologic outcomes and prognostic factors in resected stage IA pancreatic cancer: a retrospective cohort study. Co-author DOI 10.1007/s00464-026-12646-3↗
  4. Development of an artificial intelligence-based prediction platform for early recurrence of resectable pancreatic cancer after curative surgery-toward future u… First author DOI 10.4174/astr.2026.110.2.76↗
  5. Perioperative Clinical Usage of Phellinus Linteus as a Nutraceutical for Non-FOLFIRINOX-Based Postoperative Adjuvant Chemotherapy for Resected Pancreatic Cance… Co-author DOI 10.1177/15347354251353499↗
  6. Optimal Number of Lymph Nodes Retrieved to Lower the Risk of False N0 for Patients with Pancreatic Cancer Undergoing Curative Surgery. Co-author DOI 10.1245/s10434-025-18029-7↗
  7. Laparoscopic omentopexy as a spacer for carbon-ion radiotherapy in locally advanced pancreatic cancer. Co-author DOI 10.14701/ahbps.25-044↗
  8. Is There a Potential Oncologic Role for Local Therapy on Hepatic Metastasis in Patients Who Undergo Curative Pancreatectomy for Pancreatic Cancer? Co-author DOI 10.3349/ymj.2024.0078↗
  9. Immediate Postoperative AbnobaVISCUM® F as an Adjuvant Treatment in Patients Receiving Standard Care after Pancreatic Cancer Resection. Co-author DOI 10.3349/ymj.2024.0493↗
  10. Inhibition of the Alternative Complement Pathway May Cause Secretion of Factor B, Enabling an Early Detection of Pancreatic Cancer. Co-author DOI 10.1021/acs.jproteome.3c00695↗
  11. Deep-Transfer-Learning-Based Natural Language Processing of Serial Free-Text Computed Tomography Reports for Predicting Survival of Patients With Pancreatic Ca… Co-author DOI 10.1200/cci.24.00021↗
  12. Systemic inflammation response index correlates with survival and predicts oncological outcome of resected pancreatic cancer following neoadjuvant chemotherapy. Co-author DOI 10.1016/j.pan.2022.08.009↗
  13. Neoadjuvant FOLFIRINOX Followed by Pancreatoduodenectomy for Pancreatic Cancer in Patients with Previous Transhiatal Esophagectomy for Esophageal Cancer. Co-author DOI 10.1159/000525294↗
  14. Laparoscopic radical distal pancreatosplenectomy with celiac axis excision following neoadjuvant chemotherapy for locally advanced pancreatic cancer. Co-author DOI 10.14701/ahbps.21-097↗
  15. Should the Splenic Vein Be Preserved-Fate of Sinistral Portal Hypertension after Pancreatoduodenectomy with Vascular Re-Section for Pancreatic Cancer. Co-author DOI 10.3390/cancers14194853↗
  16. Biologic behavior of resected BRCA-mutated pancreatic cancer: Comparison with sporadic pancreatic cancer and other BRCA-related cancers. Co-author DOI 10.1016/j.pan.2021.02.007↗
  17. Early Diagnostic Ability of Human Complement Factor B in Pancreatic Cancer Is Partly Linked to Its Potential Tumor-Promoting Role. Co-author DOI 10.1021/acs.jproteome.1c00805↗
  18. Laparoscopic pancreaticoduodenectomy in pancreatic ductal adenocarcinoma. Co-author DOI 10.7602/jmis.2021.24.3.169↗
  19. Unexpected Para-aortic Lymph Node Metastasis in Pancreatic Ductal Adenocarcinoma: a Contraindication to Resection? Last author DOI 10.1007/s11605-019-04483-8↗
  20. Prognostic potential of the preoperative plasma complement factor B in resected pancreatic cancer: A pilot study. Co-author DOI 10.3233/cbm-181847↗
  21. The Yonsei criteria as a clinically detectable parameter for excellent prognosis in resected left-sided pancreatic cancer: outcomes of a propensity score-match… Co-author DOI 10.1007/s00464-017-5529-6↗
  22. Yonsei criteria: a clinical reflection of stage I left-sided pancreatic cancer. First author DOI 10.18632/oncotarget.22734↗
  23. Identification of an N staging system that predicts oncologic outcome in resected left-sided pancreatic cancer. Co-author DOI 10.1097/md.0000000000004035↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ho Kyoung Hwang · 20 shared papers, 2016–2026 · strength 4.56
  2. Chang Moo Kang · 19 shared papers, 2016–2026 · strength 4.22
  3. Seung Soo Hong · 8 shared papers, 2022–2026 · strength 2.54
  4. Woo Jung Lee · 10 shared papers, 2016–2022 · strength 1.52
  5. Munseok Choi · 4 shared papers, 2021–2026 · strength 1.00
  6. Seoung Yoon Rho · 3 shared papers, 2021–2026 · strength 0.82
  7. Choong‐kun Lee · 4 shared papers, 2021–2024 · strength 0.68
  8. Ji Su Kim · 3 shared papers, 2020–2022 · strength 0.53
  9. So Jeong Yoon · 2 shared papers, 2025–2026 · strength 0.53
  10. Jin Seok Heo · 2 shared papers, 2025–2026 · strength 0.53
  11. In Woong Han · 2 shared papers, 2025–2026 · strength 0.53
  12. Hongbeom Kim · 2 shared papers, 2025–2026 · strength 0.53
  13. Sang Hyun Shin · 2 shared papers, 2025–2026 · strength 0.53
  14. Hye Jin Choi · 3 shared papers, 2021–2024 · strength 0.51
  15. Juwan Kim · 2 shared papers, 2022–2025 · strength 0.49
  16. Min Jung Lee · 3 shared papers, 2019–2024 · strength 0.42
  17. Young‐Ki Paik · 3 shared papers, 2019–2024 · strength 0.42
  18. Seung‐seob Kim · 2 shared papers, 2022–2024 · strength 0.40
  19. In Soo Cho · 1 shared paper, 2026 · strength 0.39
  20. Jun Hyung Kim · 1 shared paper, 2025 · strength 0.33
  21. Ik Jae Lee · 1 shared paper, 2025 · strength 0.30
  22. Seo Hee Choi · 1 shared paper, 2025 · strength 0.30
  23. Moon Jae Chung · 1 shared paper, 2025 · strength 0.30
  24. Woong Sub Koom · 1 shared paper, 2025 · strength 0.30
  25. Sung Hwan Lee · 2 shared papers, 2017–2019 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.